• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
water filter
WATER FILTER FOR WATER PURIFIER
DUST BAG
Small dust filter
HUMIDIFIER FILTER
Oil fume adsorption filter

Taiwan, China starts study on efficacy of mixing AZ, Moderna COVID vaccines

firstwordpharmaAugust 02, 2021

Tag: AZ , Moderna , COVID vaccines

A hospital in Taiwan, China has begun a clinical study investigating a mix and match approach with COVID-19 vaccines from AstraZeneca and Moderna, Taiwan, China News reported.

Taiwan, China starts study on efficacy of mixing AZ, Moderna COVID vaccines

The trial, which is being carried out by the National Taiwan, China University Hospital (NTUH), includes four groups of 100 subjects, with the first two receiving doses of AstraZeneca and Moderna's vaccines four or eight weeks apart.

Meanwhile, the third group will receive two doses of AstraZeneca's vaccine eight weeks apart, with the final group given two doses of Moderna's vaccine, also eight weeks apart


Previous:Pfizer and Moderna raise prices for its COVID-19 vaccines in EU

Next:UK scientists believe it is 'almost certain' a coronavirus variant will emerge that beats current vaccines

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Taiwan, China starts study on efficacy of mixing AZ, Moderna COVID vaccines | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

5-(chloromethyl)-4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole

5-(chloromethyl)-4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole
(Z)-ethyl (2-cyano-2-(2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropy ridazin-3-yl)oxy)phenyl)hy

(Z)-ethyl (2-cyano-2-(2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropy ridazin-3-yl)oxy)phenyl)hy
(Z)-2-hydrazono-3-methyl-2,3-dihydrobenzo[d]thiazole

(Z)-2-hydrazono-3-methyl-2,3-dihydrobenzo[d]thiazole
(1R,2S,5S)-methyl-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylate hydrochloride

(1R,2S,5S)-methyl-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylate hydrochloride
Nicarbazine

Nicarbazine
2-Nitroimidazole (azomycin)

2-Nitroimidazole (azomycin)
ethyl 1-(2-(methylamino)pyridin-4-yl)-1H-pyrazole-4-carboxylate

ethyl 1-(2-(methylamino)pyridin-4-yl)-1H-pyrazole-4-carboxylate
methyl 2-amino-3-methyl-imidazole-4-carboxylate

methyl 2-amino-3-methyl-imidazole-4-carboxylate
1-Boc-3-(Aminomethyl)azetidine

1-Boc-3-(Aminomethyl)azetidine
Niconazole Impurity Z05

Niconazole Impurity Z05

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service